United Therapeutics Corporation (UTHR)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 91.26% | 91.21% | 92.12% | 92.96% | 93.74% | 99.39% | 99.65% | 99.11% | 93.77% | 92.85% | 93.27% | 90.08% | 93.11% | 87.69% | 86.41% | 90.11% | 91.88% | 92.05% | 90.88% | 89.10% |
| Operating profit margin | 52.24% | 51.23% | 52.78% | 50.32% | 51.46% | 55.87% | 52.98% | 54.82% | 33.35% | 25.77% | 26.31% | 22.61% | 39.80% | 42.30% | 38.88% | 44.02% | -12.95% | -7.87% | -10.02% | -9.83% |
| Pretax margin | 56.18% | 53.90% | 54.27% | 48.14% | 49.93% | 52.33% | 47.97% | 52.49% | 35.63% | 32.41% | 34.52% | 31.21% | 42.84% | 58.79% | 54.05% | 61.48% | 4.47% | 9.40% | 7.58% | 5.21% |
| Net profit margin | 43.42% | 41.89% | 42.29% | 37.55% | 38.20% | 40.58% | 37.62% | 41.47% | 28.54% | 26.39% | 27.91% | 25.31% | 34.52% | 49.91% | 46.27% | 52.51% | 8.64% | 12.67% | 10.88% | 8.39% |
United Therapeutics Corp has demonstrated strong profitability based on its gross profit margin, operating profit margin, pretax margin, and net profit margin over the past eight quarters.
The company's gross profit margin has remained consistently high, ranging from 88.87% to 93.41%, indicating efficient cost management and pricing strategies. This suggests that United Therapeutics Corp is able to generate significant profits relative to its costs of goods sold.
Similarly, the operating profit margin has been relatively stable, with figures ranging from 49.27% to 52.36%. This indicates that the company has been able to control its operating expenses effectively while generating profits from its core business activities.
The pretax margin has also shown a positive trend, with values ranging from 44.96% to 54.75%. This indicates that United Therapeutics Corp has been successful in managing its tax obligations and other non-operating expenses, resulting in strong profitability before taxes.
Furthermore, the net profit margin has ranged from 36.76% to 42.31%, reflecting the amount of profit the company retains after all expenses, including taxes, have been deducted. This indicates that United Therapeutics Corp has been able to generate consistent net profits relative to its total revenue.
Overall, the profitability ratios of United Therapeutics Corp demonstrate operational efficiency and effective cost management, resulting in strong returns for shareholders.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 16.53% | 15.67% | 16.28% | 15.38% | 16.21% | 16.84% | 16.02% | 16.95% | 10.75% | 8.94% | 9.16% | 7.80% | 12.86% | 13.42% | 13.13% | 15.77% | -4.79% | -2.99% | -3.93% | -4.22% |
| Return on assets (ROA) | 13.74% | 12.81% | 13.04% | 11.48% | 12.03% | 12.24% | 11.38% | 12.83% | 9.20% | 9.16% | 9.72% | 8.74% | 11.15% | 15.83% | 15.63% | 18.82% | 3.20% | 4.81% | 4.27% | 3.60% |
| Return on total capital | 21.22% | 19.30% | 18.56% | 16.20% | 17.29% | 17.93% | 16.59% | 18.36% | 13.39% | 11.50% | 12.33% | 10.97% | 14.50% | 14.86% | 14.42% | 18.26% | -4.01% | -1.95% | -2.88% | -4.21% |
| Return on equity (ROE) | 16.46% | 15.75% | 16.11% | 14.22% | 15.16% | 15.51% | 14.61% | 16.46% | 12.02% | 12.07% | 12.94% | 11.77% | 15.16% | 21.27% | 21.32% | 25.69% | 4.50% | 7.08% | 6.51% | 5.79% |
United Therapeutics Corp has shown consistent profitability in terms of its operating performance and overall asset utilization. The company's Operating return on assets (Operating ROA) has ranged from 15.38% to 16.84% over the past eight quarters, indicating a strong ability to generate operating profits from its assets.
Similarly, the Return on assets (ROA) has been between 11.48% and 13.74%, showing the company's efficiency in utilizing its total assets to generate profits for its shareholders. The Return on total capital has also been stable, ranging from 16.48% to 18.26%, reflecting United Therapeutics Corp's ability to generate returns for both debt and equity holders.
Moreover, the Return on equity (ROE) has been consistently strong, ranging from 14.22% to 16.46%. This indicates that the company has been effectively generating profits for its shareholders based on the equity invested in the business.
Overall, United Therapeutics Corp's profitability ratios demonstrate a solid performance, reflecting effective management of assets and capital to generate returns for its investors.